EZH2 Is Overexpressed in


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 10 12 2018
revised: 25 02 2019
accepted: 24 04 2019
pubmed: 1 5 2019
medline: 23 9 2020
entrez: 1 5 2019
Statut: ppublish

Résumé

BRCA1-deficient breast cancers carry a specific DNA copy-number signature (" EZH2 expression was analyzed in 497 breast cancers using IHC or RNA sequencing. We classified 370 tumors by copy-number profiles as The highest EZH2 expression was found in BRCA1-associated tumors harboring a Our findings demonstrate that EZH2 is expressed at significantly higher levels in

Identifiants

pubmed: 31036541
pii: 1078-0432.CCR-18-4024
doi: 10.1158/1078-0432.CCR-18-4024
doi:

Substances chimiques

Antineoplastic Agents 0
BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
Biomarkers, Tumor 0
Platinum 49DFR088MY
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4351-4362

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Julian Puppe (J)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. julian.puppe@uk-koeln.de.
Department of Obstetrics and Gynecology, Medical Faculty, University Hospital Cologne, Cologne, Germany.
Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.

Mark Opdam (M)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Philip C Schouten (PC)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Katarzyna Jóźwiak (K)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Esther Lips (E)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Tesa Severson (T)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Marieke van de Ven (M)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Chiara Brambillasca (C)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Peter Bouwman (P)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Olaf van Tellingen (O)

Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

René Bernards (R)

Oncode Institute, Utrecht, the Netherlands.
Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Jelle Wesseling (J)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Christian Eichler (C)

Department of Obstetrics and Gynecology, Medical Faculty, University Hospital Cologne, Cologne, Germany.

Fabinshy Thangarajah (F)

Department of Obstetrics and Gynecology, Medical Faculty, University Hospital Cologne, Cologne, Germany.

Wolfram Malter (W)

Department of Obstetrics and Gynecology, Medical Faculty, University Hospital Cologne, Cologne, Germany.

Gaurav Kumar Pandey (GK)

Oncode Institute, Utrecht, the Netherlands.
Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Luka Ozretić (L)

Department of Pathology, University Hospital of Cologne, Cologne, Germany.

Carlos Caldas (C)

CRUK Cambridge Institute, Cambridge, UK.

Maarten van Lohuizen (M)

Oncode Institute, Utrecht, the Netherlands.
Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Michael Hauptmann (M)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Kerstin Rhiem (K)

Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.

Eric Hahnen (E)

Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.

H Christian Reinhardt (HC)

Clinic I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.

Reinhard Büttner (R)

Department of Pathology, University Hospital of Cologne, Cologne, Germany.

Peter Mallmann (P)

Department of Obstetrics and Gynecology, Medical Faculty, University Hospital Cologne, Cologne, Germany.

Birgid Schömig-Markiefka (B)

Department of Pathology, University Hospital of Cologne, Cologne, Germany.

Rita Schmutzler (R)

Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.

Sabine Linn (S)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Jos Jonkers (J)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH